NCI's Early Detection Research Network and Cancer Diagnostic Tests

Infographic: NCI's Early Detection Research Network and Cancer Diagnostic Tests

The Early Detection Research Network has helped six cancer diagnostic tests achieve FDA-approval.

  1. One combined test to assess the risk for hepatocellular cancer: DCP and AFP-L3
  2. Two tests help to determine the need for prostate biopsies: %[2]proPSA and PCA3
  3. Three tests help to predict risk of ovarian cancer in women with a pelvic mass: OVA1TM, OveraTM and a combined test known as ROMATM with CA125 and HE4